Picture of Edisun Power Europe AG logo

ESUN Edisun Power Europe AG News Story

0.000.00%
ch flag iconLast trade - 00:00
UtilitiesSpeculativeSmall CapMomentum Trap

Swiss stocks - Factors to watch on Sept. 11

ZURICH, Sept 11 (Reuters) - The following are some of the 
main factors expected to affect Swiss stocks on Monday. 
     
    NOVARTIS  NOVN.S  ROCHE  ROG.S  
    Swiss drugmaker Novartis notched a trial win for its drug 
cocktail against skin cancer on Monday, while a rival treatment 
from Roche with slipping sales failed in a separate study with a 
similar patient group.  urn:newsml:reuters.com:*:nL5N1LR0R1 
     
    NESTLE  NESN.S  
    Germany's Merck KGaA has hired JP Morgan to sell its 
consumer health business, with Switzerland's Nestle among those 
being sounded out as a potential buyer.  urn:newsml:reuters.com:*:nL8N1LP4ZC 
    For more click  NESN.S  
 
    SWISS RE  SRENH.S  
    Walter Kielholz, chairman of the world's second-largest 
reinsurer, told newspaper Schweiz am Wochenende it was still too 
early to provide loss estimates for Hurricanes Harvery and Irma. 
"Certainly, the size of damages will be large. Swiss Re will 
also be affected by that," Kielholz said. Maximum claims payouts 
and the tendency for premiums to rise after large events meant 
natural catastrophes did not pose a large risk for Swiss Re as a 
reinsurer, the 66-year-old said.  SRENH.S  
     
    ROCHE 
    The drugmaker's  ROG.S  Genentech subsidiary said late on 
Friday that a study of the Lampalizumab treament for age-related 
macular degeneration, a form of blindness, did not meet its 
primary endpoint. Analysts had forecast sales for the drug to 
reach around 1.5 billion Swiss francs  ($1.59 billion) by 2023, 
though the trial raises questions about its potential. 
 urn:newsml:reuters.com:*:nASB0BIO5 
    For more news, click on  ROG.S  
     
    COMPANY STATEMENTS  CPR-CH  
    * Edisun Power Group  ESUN.S  said it has carried out a 
capital increase of 5.1 million francs.  ESUN.S  
    * Novartis  NOVN.S  said a five-year study of its Lucentis 
eye medicine reconfirmed its effectiveness when compared to 
Regeneron's  REGN.O  Eylea. 
 
    ECONOMY  M-CH  
    The Swiss National Bank is due to release data on sight 
deposits at 0800 GMT.  
 
($1 = 0.9455 Swiss francs) 
 
 (Reporting by Zurich newsroom) 
 ((+41 58 306 7336)(zurich.newsroom@thomsonreuters.com)) 
  
((For Top News in a multimedia Web format on Eikon visit: 
https://emea1.views.cp.extranet.thomsonreuters.biz/Explorer/NEWSxTOPNEWS.aspx?group=SP_GROUP_001&page=SP_PAGE_001&pageName=FrontPage 
 FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON: 
     
 Daily Swiss stock market report in German................ .SDE  
 All SMI constituent stocks............................ 0#.SSMI   
 News on major Swiss stock price moves.................. CH-HOT  
 FTSE Eurotop 300 index................................  .FTEU3  
 DJ STOXX index........................................  .STOXX  
 Top 10 STOXX sectors.............................  .PGL.STOXXS   
 Top 10 EUROSTOXX sectors........................  .PGL.STOXXES  
 Top 10 Eurotop 300 sectors.......................  .PGL.FTEU3S  
 Top 25 European pct gainers...  .PG.PEUR , losers...  .PL.PEUR  
     
 Swiss mid-cap index      .SSMI   SMI futures            0#SMI:  
 Swiss all-share index    .SSHI   Market statistics   CH/STATS1  
 Swiss market digest      .AD.S   Sector overview    CH/SECTOR1  
 All Swiss news              CH   Swiss research news     CH-RCH    
 All equity news              E   
      
 INTERNET ADDRESSES:               
  
Swiss Exchange  www.swx.ch/      
Eurex   www.eurexchange.com 
STOXX Ltd         www.stoxx.com  
  
 SPEED GUIDES:  VX/EQUITY   EQUITY   EQUITY/NEWS1   EUR/EQUITY   
  SWITZERLAND   REUTERS  )) 
 
Keywords: MARKETS SWISS STOCKS/

Recent news on Edisun Power Europe AG

See all news